Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
Achieve Life Sciences appointed Jeffrey Farrow and Reid Waldman, MD to its Board of Directors to bolster commercial and strategic oversight ahead of its NDA resubmission for cytisinicline. Farrow brings extensive late-stage launch experience, having served as CFO for three biopharma companies acquired for a combined $9 billion, including Global Blood Therapeutics and Hyperion Therapeutics. Waldman, CEO of Veradermics (MANE), adds clinical and commercial expertise in dermatology and aesthetics, having led his company through a $294.8M IPO and subsequent $472M follow-on financing.
Key figures
- Farrow acquisition value
- $9 billion
- Veradermics ipo proceeds
- $294.8 million
- Veradermics follow on proceeds
- $472 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.